Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 8, 2012, Pages 495-503

  Lu, Ping ^a   Yu, Baodan ^a   Xu, Jun ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cucurbitacin B; dendritic cells; immature myeloid cells; JAK2 STAT3 signaling; lung cancer; p53 specific T cells

Indexed keywords

CUCURBITACIN; CUCURBITACIN B; GAMMA INTERFERON; JANUS KINASE 2; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; TUMOR CELL;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; HUMANS; JANUS KINASE 2; LUNG NEOPLASMS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; TRITERPENES;

EID: 84867512289     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1219     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006;56:106.
2. O'Mahony D, Kummar S, Martin E. Gutierrez. Non-small-cell lung cancer vaccine therapy: A concise review. J Clin Oncol 2005;23:9022.
3. Takahashi T, Nau MM, Chiba I, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 1989;246:491.
4. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5:1079.
5. Nikitina EY, Clark JI, van Beynen J, et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7:127.
6. Nikitina EY, Chada S, Muro-Cacho C, et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002;9:345.
7. van der Burg SH, Menon AG, Redeker A, et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 2002;8:1019.
8. Svane IM, Pedersen AE, Johnsen HE, et al. Vaccination with p53-peptide-pulsed dendritic cells of patients with advanced breast cancer: Report from a phase I study. Cancer Immunol Immunother 2004;53:633.
9. Kuball J, Wen SF, Leissner J, et al. Successful adenovirusmediatedwild -type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002;20:957.
10. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878.
11. Gabrilovich DI, Velders M, Sotomayor E, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol 2001;166:5398.
12. Bronte V, Serafini P, Appoloni E, et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother 2001;24:431.
13. Shurin G, Shurin M, Bykovskaia S, et al. Neuroblastomaderived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001;61:363.
14. Hoffmann TK, Mü ller-Berghaus J, Ferris RL, et al. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002;8: 1787.
15. Rane SG, Reddy EP. Janus kinases: Components of multiple signaling pathways. Oncogene 2000;19:5662.
16. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474.
17. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945.
18. Yu H, Jove R. The STATS of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97.
19. NefedovaY, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004;172:464.
20. Park S-J, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004;173:3844.
21. Nefedova Y, Nagaraj S, Rosenbauer A, et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic- selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525.
22. Sun J, Blaskovich MA, Jovel R, et al. Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24:3236.
23. Fulda S, Sieverts H, Friesen C, et al. Cancer Res 1997;57:3823.
24. Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442.
25. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005;16:601.
26. Chen C, Qiang S, Lou L, et al. Cucurbitane type triterpenoids from the stems of Cucumis melo. J Nat Prod 2009; 72:824.
27. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2002;2:381.
28. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211.
29. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J Immunol 2001; 166:678.
30. Cameron DJ. Inhibitory factors derived from human tumors: Isolation of factors which suppress macrophage mediated cytotoxicity. Int J Immunopharmacol 1983;5:345.
31. Oshiro MM, Landowski TH, Catlett-Falcone R, et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001; 7:4262.
32. Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glycosides: Structures and biological activities. Nat Prod Rep 2005;22:386.